Market Overview:
The global pirfenidone market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of IPF, increasing awareness about IPF, and growing demand for better treatment options for IPF. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The global pirfenidone market can be segmented on the basis of type into tablet, capsule, and other. The tablet segment is expected to account for a major share in terms of revenue in 2018 owing to its higher adoption rates as compared to other types. On the basis of application, the global pirfenidone market can be divided into mild idiopathic pulmonary fibrosis (IPF), moderate idiopathic pulmonary fibrosis (IPF), and other applications.
Product Definition:
Pirfenidone is a medication that is used to treat the symptoms of idiopathic pulmonary fibrosis. Pirfenidone can improve breathing and slow down the progression of the disease.
Tablet:
Tablet is a form of oral solid dosage drug delivery systems that are manufactured in the shape of a tablet. It’s major application is in pharmaceutical industries for the packaging and administration of active ingredients used in tablets, capsules, and other forms. The tablet can be divided into two categories: film-coated tablets & enteric coated tablets.
Capsule:
Capsules are small containers made up of gelatin, polyvinyl chloride or other materials. They protect active ingredients from light, moisture and air. Capsules can be opened and consumed directly or may be dissolved in a liquid prior to consumption.
Application Insights:
Mild IPF dominated the global market in terms of revenue in 2017. This is attributed to the availability of effective treatment options for mild cases of IPF and high unmet medical needs due to its moderate nature. As per a study published by NCBI, around 60%of patients with IPA suffer from mild disease only, while 40%of them have no symptoms at all.
Moderate ITP followed closely by mild IPA as far as prevalence is concerned owing to higher incidence rates and better prognosis associated with it globally. According to data published by WHO, around 5-10%of people above 60 years have ITP every year worldwide while 20-30%are affected during winter season across different parts of the world including Europe, North America and Asia Pacific region respectively which points towards a significant demand for pirfenidone tablets & capsules globally over the forecast period especially in moderate cases of IPF & Mild Idiopathic Pulmonary Fibrosis (IPA).
Regional Analysis:
North America was the largest market for pyrifenidone, accounting for a share of more than 30.0% in 2017. The region is expected to maintain its dominance over the forecast period as well due to favorable reimbursement policies and increasing healthcare expenditure in the U.S., which has led to an increase in R&D activities for new drug development.
In addition, growing demand from other regions such as Europe and Asia Pacific is expected to fuel growth over the next eight years owing to an increase in disease prevalence rates coupled with rising government initiatives towards improving healthcare infrastructure especially within emerging markets such as India.
Growth Factors:
- Increasing incidence of idiopathic pulmonary fibrosis (IPF)
- Growing awareness about Pirfenidone as a potential treatment for IPF
- Rising demand for better and more effective therapies for IPF
- Availability of reimbursement for Pirfenidone in some countries
- Entry of new players in the market
Scope Of The Report
Report Attributes
Report Details
Report Title
Pirfenidone Market Research Report
By Type
Tablet, Capsule, Other
By Application
Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis, Other
By Companies
Genentech (Roche), Shionogi, GNI Group, Beijing Continent, Cipla, Lupin Ltd, Zydus Cadila, Glenmark Pharmaceuticals, Koye Pharmaceuticals, MSN Laboratories, Wockhardt, Incepta Pharmaceuticals, Unimed Unihealth
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Pirfenidone Market Report Segments:
The global Pirfenidone market is segmented on the basis of:
Types
Tablet, Capsule, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genentech (Roche)
- Shionogi
- GNI Group
- Beijing Continent
- Cipla
- Lupin Ltd
- Zydus Cadila
- Glenmark Pharmaceuticals
- Koye Pharmaceuticals
- MSN Laboratories
- Wockhardt
- Incepta Pharmaceuticals
- Unimed Unihealth
Highlights of The Pirfenidone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablet
- Capsule
- Other
- By Application:
- Mild Idiopathic Pulmonary Fibrosis
- Moderate Idiopathic Pulmonary Fibrosis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pirfenidone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pirfenidone is a medication used to treat various types of cancer. It works by stopping the growth of cancer cells.
Some of the major players in the pirfenidone market are Genentech (Roche), Shionogi, GNI Group, Beijing Continent, Cipla, Lupin Ltd, Zydus Cadila, Glenmark Pharmaceuticals, Koye Pharmaceuticals, MSN Laboratories, Wockhardt, Incepta Pharmaceuticals, Unimed Unihealth.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pirfenidone Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pirfenidone Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pirfenidone Market - Supply Chain
4.5. Global Pirfenidone Market Forecast
4.5.1. Pirfenidone Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pirfenidone Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pirfenidone Market Absolute $ Opportunity
5. Global Pirfenidone Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pirfenidone Market Size and Volume Forecast by Type
5.3.1. Tablet
5.3.2. Capsule
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pirfenidone Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pirfenidone Market Size and Volume Forecast by Application
6.3.1. Mild Idiopathic Pulmonary Fibrosis
6.3.2. Moderate Idiopathic Pulmonary Fibrosis
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pirfenidone Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pirfenidone Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pirfenidone Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pirfenidone Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pirfenidone Demand Share Forecast, 2019-2026
9. North America Pirfenidone Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pirfenidone Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pirfenidone Market Size and Volume Forecast by Application
9.4.1. Mild Idiopathic Pulmonary Fibrosis
9.4.2. Moderate Idiopathic Pulmonary Fibrosis
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pirfenidone Market Size and Volume Forecast by Type
9.7.1. Tablet
9.7.2. Capsule
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pirfenidone Demand Share Forecast, 2019-2026
10. Latin America Pirfenidone Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pirfenidone Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pirfenidone Market Size and Volume Forecast by Application
10.4.1. Mild Idiopathic Pulmonary Fibrosis
10.4.2. Moderate Idiopathic Pulmonary Fibrosis
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pirfenidone Market Size and Volume Forecast by Type
10.7.1. Tablet
10.7.2. Capsule
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pirfenidone Demand Share Forecast, 2019-2026
11. Europe Pirfenidone Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pirfenidone Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pirfenidone Market Size and Volume Forecast by Application
11.4.1. Mild Idiopathic Pulmonary Fibrosis
11.4.2. Moderate Idiopathic Pulmonary Fibrosis
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pirfenidone Market Size and Volume Forecast by Type
11.7.1. Tablet
11.7.2. Capsule
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analyis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pirfenidone Demand Share, 2019-2026
12. Asia Pacific Pirfenidone Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pirfenidone Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pirfenidone Market Size and Volume Forecast by Application
12.4.1. Mild Idiopathic Pulmonary Fibrosis
12.4.2. Moderate Idiopathic Pulmonary Fibrosis
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pirfenidone Market Size and Volume Forecast by Type
12.7.1. Tablet
12.7.2. Capsule
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pirfenidone Demand Share, 2019-2026
13. Middle East & Africa Pirfenidone Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pirfenidone Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pirfenidone Market Size and Volume Forecast by Application
13.4.1. Mild Idiopathic Pulmonary Fibrosis
13.4.2. Moderate Idiopathic Pulmonary Fibrosis
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pirfenidone Market Size and Volume Forecast by Type
13.7.1. Tablet
13.7.2. Capsule
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pirfenidone Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pirfenidone Market: Market Share Analysis
14.2. Pirfenidone Distributors and Customers
14.3. Pirfenidone Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Genentech (Roche)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shionogi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GNI Group
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Beijing Continent
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cipla
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Lupin Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Zydus Cadila
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Glenmark Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Koye Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. MSN Laboratories
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Wockhardt
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Incepta Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Unimed Unihealth
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
